CoChat

The locus coeruleus contributes to the anorectic, nausea, and autonomic physiological effects of glucagon-like peptide-1

Open access

The DOI matches its Crossref record; 124 of the 124 references it cites were found in a registry or an index.

Abstract

Increasing the therapeutic potential and reducing the side effects of U.S. Food and Drug Administration-approved glucagon-like peptide-1 receptor (GLP-1R) agonists used to treat obesity require complete characterization of the central mechanisms that mediate both the food intake-suppressive and illness-like effects of GLP-1R signaling. Our studies, in the rat, demonstrate that GLP-1Rs in the locus coeruleus (LC) are pharmacologically and physiologically relevant for food intake control. Furthermore, agonism of LC GLP-1Rs induces illness-like behaviors, and antagonism of LC GLP-1Rs can attenuate GLP-1R-mediated nausea. Electrophysiological and behavioral pharmacology data support a role for LC GLP-1Rs expressed on presynaptic glutamatergic terminals in the control of feeding and malaise. Collectively, our work establishes the LC as a site of action for GLP-1 signaling and extends our understanding of the GLP-1 signaling mechanism necessary for the development of improved obesity pharmacotherapies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1126/sciadv.adh0980

Cites

124 of 124 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1. LC GLP-1Rs mediate food intake and body weight control. (A) Direct administration of Ex-4 to the LC reduced chow intake at 6 hours after administration (n = 13). (B) LC Ex-4 suppressed food intake at 24 hours after administration (n = 13). (C) LC Ex-4 had a dose-dependent effect on body weight suppression measured 24 hours after administration (n = 13). (D) In a separate cohort of rats (n = 8), 0.05 μg of Ex-4 suppressed only dark cycle intake, while Ex-9 (10 μg) had no effect on dark or light cycle intake. (E) Body weight measured over 24 hours was reduced by LC Ex-4 and not affected by LC Ex-9 (n = 8). (F) Changes in food intake during the dark cycle by LC Ex-4 were mediated by a reduction in meal size (n = 8). (G) The number of meals consumed during either the dark or light cycle was not affected by LC Ex-4 or LC Ex-9 (n = 8). (H) Food intake suppression by LiCl (0.15 M; 20 ml/kg) at 6 hours was attenuated by LC Ex-9 (n = 12). (I) Attenuation of LiCl-induced food intake suppression at 24 hours was not observed at 24 hours (n = 12). (J) No effects on 24-hour body weight change were observed following LiCl or Ex-9 treatment combinations (n = 12). All data are expressed as means ± SEM. Data in (A) to (G) were analyzed with a repeated-measures one-way analysis of variance (ANOVA) at each time point followed by Newman Keuls post hoc tests. Data in (H) to (J) were analyzed with repeated-measures two-way ANOVA followed by Newman-Keuls post hoc tests. Means with different letters are significantly different from each other (P < 0.05). Veh, vehicle.
Fig. 1. LC GLP-1Rs mediate food intake and body weight control. (A) Direct administration of Ex-4 to the LC reduced chow intake at 6 hours after administration (n = 13). (B) LC Ex-4 suppressed food intake at 24 hours after administration (n = 13). (C) LC Ex-4 had a dose-dependent effect on body weight suppression measured 24 hours after administration (n = 13). (D) In a separate cohort of rats (n = 8), 0.05 μg of Ex-4 suppressed only dark cycle intake, while Ex-9 (10 μg) had no effect on dark or light cycle intake. (E) Body weight measured over 24 hours was reduced by LC Ex-4 and not affected by LC Ex-9 (n = 8). (F) Changes in food intake during the dark cycle by LC Ex-4 were mediated by a reduction in meal size (n = 8). (G) The number of meals consumed during either the dark or light cycle was not affected by LC Ex-4 or LC Ex-9 (n = 8). (H) Food intake suppression by LiCl (0.15 M; 20 ml/kg) at 6 hours was attenuated by LC Ex-9 (n = 12). (I) Attenuation of LiCl-induced food intake suppression at 24 hours was not observed at 24 hours (n = 12). (J) No effects on 24-hour body weight change were observed following LiCl or Ex-9 treatment combinations (n = 12). All data are expressed as means ± SEM. Data in (A) to (G) were analyzed with a repeated-measures one-way analysis of variance (ANOVA) at each time point followed by Newman Keuls post hoc tests. Data in (H) to (J) were analyzed with repeated-measures two-way ANOVA followed by Newman-Keuls post hoc tests. Means with different letters are significantly different from each other (P < 0.05). Veh, vehicle.CC BY · PubMed Central
Fig. 2. LC GLP-1Rs mediate tachycardia, hypothermia, and gastric emptying rate. (A) LC Ex-4, injected at the onset of the 12-hour dark cycle (gray), induced tachycardia relative to vehicle-treated rats (n = 10). (B) When quantified in 3-hour bins, LC Ex-4 induced tachycardia at all measured time points over 24 hours (n = 10). (C) LC Ex-4, injected at the onset of the 12-hour dark cycle (gray), induced hypothermia relative to vehicle-treated rats (n = 10). (D) When quantified in 3-hour bins, LC Ex-4 induced hypothermia during the first 9 hours after administration. (E) LC Ex-4 did not change cumulative locomotor counts over 24 hours (n = 10). (F) Intraperitoneal (ip) injection of clonidine (0.1 mg/kg) significantly increased pupil dilation relative to vehicle-injected rats (left; n = 5). However, LC Ex-4 (0.05 μg) did not affect pupil dilation (right) (n = 7). (G) LC Ex-4 did not affect plasma corticosterone release at 90 min after administration (n = 11). (H) The gastric emptying rate of gavaged acetaminophen in Ensure (40 mg/6 ml) was reduced by LC Ex-4 relative to vehicle-treated rats (n = 14). (I) When quantified as an area under the curve (AUC), plasma acetaminophen concentrations were reduced by both 0.025 and 0.05 μg of Ex-4 (n = 14). All data were expressed as means ± SEM. Binned data in (B) and (D) and data in (E) to (G) were analyzed with Student’s t test at each time point. Data in (I) were analyzed with a repeated-measures one-way ANOVA followed by Newman-Keuls post hoc tests. Means with different letters are significantly different from each other (P < 0.05) and *P < 0.05. BPM, beats per minute.
Fig. 2. LC GLP-1Rs mediate tachycardia, hypothermia, and gastric emptying rate. (A) LC Ex-4, injected at the onset of the 12-hour dark cycle (gray), induced tachycardia relative to vehicle-treated rats (n = 10). (B) When quantified in 3-hour bins, LC Ex-4 induced tachycardia at all measured time points over 24 hours (n = 10). (C) LC Ex-4, injected at the onset of the 12-hour dark cycle (gray), induced hypothermia relative to vehicle-treated rats (n = 10). (D) When quantified in 3-hour bins, LC Ex-4 induced hypothermia during the first 9 hours after administration. (E) LC Ex-4 did not change cumulative locomotor counts over 24 hours (n = 10). (F) Intraperitoneal (ip) injection of clonidine (0.1 mg/kg) significantly increased pupil dilation relative to vehicle-injected rats (left; n = 5). However, LC Ex-4 (0.05 μg) did not affect pupil dilation (right) (n = 7). (G) LC Ex-4 did not affect plasma corticosterone release at 90 min after administration (n = 11). (H) The gastric emptying rate of gavaged acetaminophen in Ensure (40 mg/6 ml) was reduced by LC Ex-4 relative to vehicle-treated rats (n = 14). (I) When quantified as an area under the curve (AUC), plasma acetaminophen concentrations were reduced by both 0.025 and 0.05 μg of Ex-4 (n = 14). All data were expressed as means ± SEM. Binned data in (B) and (D) and data in (E) to (G) were analyzed with Student’s t test at each time point. Data in (I) were analyzed with a repeated-measures one-way ANOVA followed by Newman-Keuls post hoc tests. Means with different letters are significantly different from each other (P < 0.05) and *P < 0.05. BPM, beats per minute.CC BY · PubMed Central
Fig. 3. LC GLP-1Rs mediate kaolin consumption. (A) Direct administration of Ex-4 to the LC induced an increase in kaolin intake (n = 5) relative to vehicle-treated rats (n = 5) at 3, 6, and 24 hours after administration. (B) Kaolin intake induced by LiCl at 1, 3, 6, and 24 hours was attenuated by bilateral LC Ex-9 (10 μg/100 nl) (n = 12). All data were expressed as means ± SEM. Data in (A) were analyzed with a repeated-measures one-way ANOVA at each time point followed by Newman-Keuls post hoc tests. Data in (B) were analyzed with repeated-measures two-way ANOVA followed by Newman-Keuls post hoc tests. Means with different letters are significantly different from each other (P < 0.05).
Fig. 3. LC GLP-1Rs mediate kaolin consumption. (A) Direct administration of Ex-4 to the LC induced an increase in kaolin intake (n = 5) relative to vehicle-treated rats (n = 5) at 3, 6, and 24 hours after administration. (B) Kaolin intake induced by LiCl at 1, 3, 6, and 24 hours was attenuated by bilateral LC Ex-9 (10 μg/100 nl) (n = 12). All data were expressed as means ± SEM. Data in (A) were analyzed with a repeated-measures one-way ANOVA at each time point followed by Newman-Keuls post hoc tests. Data in (B) were analyzed with repeated-measures two-way ANOVA followed by Newman-Keuls post hoc tests. Means with different letters are significantly different from each other (P < 0.05).CC BY · PubMed Central
Fig. 4. LC GLP-1R activation increases glutamate signaling onto LC NE neurons. (A) Voltage-clamp electrophysiology recordings of TH+ enhanced green fluorescent protein–labeled LC NE neurons. (B) Representative traces showing bath applied Ex-4 (1 μM) increased the frequency of spontaneous excitatory postsynaptic currents (EPSCs). Bath application of the AMPA-type glutamate receptor antagonist 2,3-dihydroxy-6-nitro-7-sulfamoylbenzo[f]quinoxaline (NBQX) eliminated the phasic waveforms. (C) The majority of recorded neurons (n = 8 of 10, 80%) responded to bath applied Ex-4. (D) Ex-4 significantly increased the frequency of spontaneous EPSCs. (E) Ex-4 also increased the amplitude of EPSCs in responsive neurons (n = 8). (F) The decay kinetics (tau) were not affected by Ex-4 application relative to control (n = 8). All data were expressed as means (D and F) or median (E) ± SEM. All data were analyzed with paired Student’s t tests (D and F) or Wilcoxon signed-rank test (E). Means with different letters are significantly different from each other (P < 0.05).
Fig. 4. LC GLP-1R activation increases glutamate signaling onto LC NE neurons. (A) Voltage-clamp electrophysiology recordings of TH+ enhanced green fluorescent protein–labeled LC NE neurons. (B) Representative traces showing bath applied Ex-4 (1 μM) increased the frequency of spontaneous excitatory postsynaptic currents (EPSCs). Bath application of the AMPA-type glutamate receptor antagonist 2,3-dihydroxy-6-nitro-7-sulfamoylbenzo[f]quinoxaline (NBQX) eliminated the phasic waveforms. (C) The majority of recorded neurons (n = 8 of 10, 80%) responded to bath applied Ex-4. (D) Ex-4 significantly increased the frequency of spontaneous EPSCs. (E) Ex-4 also increased the amplitude of EPSCs in responsive neurons (n = 8). (F) The decay kinetics (tau) were not affected by Ex-4 application relative to control (n = 8). All data were expressed as means (D and F) or median (E) ± SEM. All data were analyzed with paired Student’s t tests (D and F) or Wilcoxon signed-rank test (E). Means with different letters are significantly different from each other (P < 0.05).CC BY · PubMed Central
Fig. 5. LC GLP-1R activation contributes to food intake control via enhanced glutamate signaling. (A) RNAscope analysis did not reveal Glp1r mRNA expression in LC NE neuron (DBH) soma. (B) LC NE neurons express N-methyl-d-aspartate (NMDA) receptors (Grin1A). (C) LC NE neurons express AMPA receptors (GluA1). (D) Pretreatment with an NMDA/AMPA antagonist cocktail [GluR antag; MK-801, 0.05 μg/CNQX (6-cyano-7-nitroquinoxaline-2,3-dione), 0.3 μg] attenuated the food intake-suppressive effects of LC Ex-4 (0.05 μg) at 3 and 6 hours after administration (n = 20). (E) MK-801/CNQX attenuated the food intake suppressive effects of LC Ex-4 at 24 hours (n = 20). (F) Twenty-four-hour body weight reduction by LC Ex-4 was not significantly affected by MK-801/CNQX pretreatment (n = 20). (G) Proposed mechanism by which LC GLP-1R activation increases LC NE activity, suppresses food intake, and causes illness-like and autonomic effects. All data were expressed as means ± SEM. Data in (D) to (F) were analyzed with a repeated-measures two-way ANOVA at each time point followed by Newman-Keuls post hoc tests. Means with different letters are significantly different from each other (P < 0.05). DAPI, 4′,6-diamidino-2-phenylindole.
Fig. 5. LC GLP-1R activation contributes to food intake control via enhanced glutamate signaling. (A) RNAscope analysis did not reveal Glp1r mRNA expression in LC NE neuron (DBH) soma. (B) LC NE neurons express N-methyl-d-aspartate (NMDA) receptors (Grin1A). (C) LC NE neurons express AMPA receptors (GluA1). (D) Pretreatment with an NMDA/AMPA antagonist cocktail [GluR antag; MK-801, 0.05 μg/CNQX (6-cyano-7-nitroquinoxaline-2,3-dione), 0.3 μg] attenuated the food intake-suppressive effects of LC Ex-4 (0.05 μg) at 3 and 6 hours after administration (n = 20). (E) MK-801/CNQX attenuated the food intake suppressive effects of LC Ex-4 at 24 hours (n = 20). (F) Twenty-four-hour body weight reduction by LC Ex-4 was not significantly affected by MK-801/CNQX pretreatment (n = 20). (G) Proposed mechanism by which LC GLP-1R activation increases LC NE activity, suppresses food intake, and causes illness-like and autonomic effects. All data were expressed as means ± SEM. Data in (D) to (F) were analyzed with a repeated-measures two-way ANOVA at each time point followed by Newman-Keuls post hoc tests. Means with different letters are significantly different from each other (P < 0.05). DAPI, 4′,6-diamidino-2-phenylindole.CC BY · PubMed Central
Fig. 6. LC GLP-1Rs contribute to the therapeutic and illness-like effects of semaglutide. (A) Representative images of increased neural activity (c-Fos; green) of LC NE neurons (TH+) by peripheral administration of semaglutide (Sema; 10 nmol/kg; ip) compared to vehicle. (B) Quantification revealed a significant increase in the percentage of c-Fos+ LC NE neurons in ip semaglutide (n = 5) relative to vehicle (n = 4) treated rats. (C) Food intake suppression by ip semaglutide (10 nmol/kg) at 3 and 6 hours was attenuated by pretreatment with LC Ex-9 (10 μg) (n = 15). (D) Food intake suppression by ip semaglutide (10 nmol/kg) at 24 hours was attenuated by pretreatment with LC Ex-9 (10 μg) (n = 15). (E) Similarly, LC Ex-9 (10 μg) attenuated body weight suppression by semaglutide (10 nmol/kg) measured 24 hours after administration (n = 15). (F) In the same cohort of rats, LC Ex-9 (10 μg) attenuated kaolin intake induced by ip semaglutide (10 nmol/kg) at 1, 3, 6, and 24 hours (n = 15). All data were expressed as means ± SEM. Data in (B) were analyzed with a Student’s t test. Data in (C) to (F) were analyzed with a repeated-measures two-way ANOVA at each time point followed by Newman-Keuls post hoc tests. Means with different letters are significantly different from each other (P < 0.05).
Fig. 6. LC GLP-1Rs contribute to the therapeutic and illness-like effects of semaglutide. (A) Representative images of increased neural activity (c-Fos; green) of LC NE neurons (TH+) by peripheral administration of semaglutide (Sema; 10 nmol/kg; ip) compared to vehicle. (B) Quantification revealed a significant increase in the percentage of c-Fos+ LC NE neurons in ip semaglutide (n = 5) relative to vehicle (n = 4) treated rats. (C) Food intake suppression by ip semaglutide (10 nmol/kg) at 3 and 6 hours was attenuated by pretreatment with LC Ex-9 (10 μg) (n = 15). (D) Food intake suppression by ip semaglutide (10 nmol/kg) at 24 hours was attenuated by pretreatment with LC Ex-9 (10 μg) (n = 15). (E) Similarly, LC Ex-9 (10 μg) attenuated body weight suppression by semaglutide (10 nmol/kg) measured 24 hours after administration (n = 15). (F) In the same cohort of rats, LC Ex-9 (10 μg) attenuated kaolin intake induced by ip semaglutide (10 nmol/kg) at 1, 3, 6, and 24 hours (n = 15). All data were expressed as means ± SEM. Data in (B) were analyzed with a Student’s t test. Data in (C) to (F) were analyzed with a repeated-measures two-way ANOVA at each time point followed by Newman-Keuls post hoc tests. Means with different letters are significantly different from each other (P < 0.05).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 32

Metadata

Authors
Fortin, S. M., Chen, J. C., Petticord, M. C., Ragozzino, F. J., Peters, J. H., & Hayes, M. R.
Affiliations
  • University of Pennsylvania (US)
  • Washington State University (US)
Corresponding author
  • Fortin, Samantha M.
  • Hayes, Matthew R.
Venue
Science Advances
Published
2023-09-22
Volume
9
Issue
38
Pages
eadh0980-eadh0980
ISSN
2375-2548 (ISSN-L)
OpenAlex
W4386905965
Cited by
32
References
123
Citations by year
2026: 11 · 2025: 12 · 2024: 8 · 2023: 1
FWCI
4.76
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Science Advances (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health
  • National Institute of Diabetes and Digestive and Kidney Diseases (R01DK115762, R01DK021397, R56DK115762, R56DK021397, K01DK133627)
Topics
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
Keywords
locus coeruleus, glucagon-like peptide-1, GLP-1 receptor agonists, food intake regulation, nausea, anorectic effect, autonomic nervous system, malaise, obesity pharmacotherapy
MeSH terms
Glucagon-Like Peptide-1 Receptor, Animals, Appetite Depressants, Locus Coeruleus, Nausea, Obesity, United States, Rats, Glucagon-Like Peptide 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.